Workflow
利润分配
icon
Search documents
成都燃气集团股份有限公司 2025年第一季度报告
Zheng Quan Ri Bao· 2025-04-18 21:50
Core Viewpoint - The company has ensured the authenticity, accuracy, and completeness of its financial reports and other disclosures, taking legal responsibility for any misleading statements or omissions [2][3][4]. Financial Data - The first quarter financial statements for 2025 are unaudited, with the company confirming that there were no profits from mergers with controlled entities in the current or previous periods [5][6]. - The company has not adopted new accounting standards or interpretations that would affect the financial statements for the year [6]. Shareholder Information - The company has reported that there are no changes in the major shareholders or their shareholding status compared to the previous period [4]. Supervisory Board Meeting - The third supervisory board meeting was held on April 18, 2025, with all five supervisors present, and the meeting followed legal and procedural requirements [7]. - The supervisory board approved several key resolutions, including the annual work report, annual report and summary, profit distribution plan, and the special report on the use of raised funds [8][10][13][15]. Financial Reports and Budgets - The supervisory board confirmed that the 2024 annual financial statements accurately reflect the company's financial status and operational results, and the 2025 budget is deemed reasonable [17]. - The board also approved the evaluation report on internal controls, affirming that the company has established a sound internal control system [29]. Related Party Transactions - The supervisory board reviewed and approved the execution of related party transactions for 2024 and the expected transactions for 2025, confirming that they are conducted fairly and do not harm the interests of the company or its shareholders [20][25][26]. Accounting Estimates - The board approved changes in accounting estimates, stating that they provide a more reliable and relevant reflection of the company's financial status [27]. Quarterly Report - The supervisory board reviewed the first quarter report for 2025, confirming that it complies with legal and regulatory requirements and accurately reflects the company's operational and financial conditions [30].
浙江龙盛:2024年净利润20.3亿元,同比增长32.36% 拟10派2.5元
news flash· 2025-04-14 10:01
浙江龙盛(600352)公告,2024年营业收入158.84亿元,同比增长3.79%。归属于上市公司股东的净利 润20.3亿元,同比增长32.36%。基本每股收益0.632元/股,同比增长30.01%。公司2024年度拟以实施 权益分派股权登记日登记的总股本为基数分配利润,每10股派发现金红利2.5元(含税),剩余未分配利润 结转下一年度。资本公积金不转增股本。 ...
抚顺特殊钢股份有限公司2024年年度报告摘要
Group 1 - The company operates in the special steel and alloy materials sector, focusing on high-temperature alloys, ultra-high-strength steel, stainless steel, and tool steel, with applications in aerospace, energy, petrochemicals, and transportation [8][14][15] - The company reported a steel production of 603,900 tons in 2024, a decrease of 10.91% year-on-year, and a steel product output of 440,500 tons, down 13.04% year-on-year, while "three high and one special" products increased by 14.25% [18] - The company achieved an operating income of 8.484 billion yuan, a decrease of 1.06% year-on-year, and a net profit of 112 million yuan, down 69.18% year-on-year [18] Group 2 - The steel industry in China is facing overcapacity and weak demand, with traditional sectors like real estate and infrastructure showing only a "weak recovery," while emerging demands in new energy and electric vehicles are growing [4][3] - The global crude steel production in 2024 is projected to be 1.883 billion tons, a year-on-year decrease of 0.8%, with China's crude steel output at 1.005 billion tons, a slight decline [3] - The special steel industry is experiencing intensified competition in mid-low and mid-high-end products, while high-end products still lag behind developed countries in quality and stability [6][7] Group 3 - The company has established long-term procurement agreements with quality suppliers for raw materials, ensuring stable supply channels [10] - The production model is based on customer orders, with a focus on efficiency and flexibility in production planning [11] - The company has implemented a quality monitoring system certified by ISO9001 and AS9100, enhancing its quality management capabilities [13] Group 4 - The company plans to distribute a cash dividend of 0.018 yuan per share, totaling approximately 35.32 million yuan, which accounts for 31.62% of the net profit attributable to shareholders [1] - The company is seeking a comprehensive credit facility of up to 6.5 billion yuan for operational funding in 2025 [46][79] - The company has proposed to continue its bill pool business with a limit of 800 million yuan to improve liquidity and reduce management costs [49][81]
零售业薪资天花板?胖东来店长月薪7.8万,员工近1万
Sou Hu Cai Jing· 2025-04-11 18:52
在3月28日举办的"2025中国超市周"主题演讲中,胖东来掌门人于东来首次公开了企业八级薪酬体系的 具体数据。根据最新统计,扣除社保后,今年前两个月基层员工平均实发薪资达9886元/月,门店店长 平均月收入更是高达78058元,管理层薪资整体较去年有显著提升。 于东来特别说明,为配合"梦之城"等重大项目建设(预计总投资50-70亿元),企业调整了利润分配策 略。"未来几年我们将集中资金用于战略投资,但必须保障管理团队生活质量,因此选择通过涨薪方式 实现平衡。" 谈及企业经营状况,这位零售业领军人物透露,今年首季度已实现62亿元销售额,全年目标将控制在 200亿元规模。"预计产生约10亿元利润,这些资金将全部用于升级门店设施,最终回馈社会。"于东来 强调,企业拒绝盲目扩张,更关注服务品质与社会价值的提升。 胖东来薪资为何那么高? 为何这家区域零售企业能开出如此高薪?背后究竟有何经营逻辑? 1.高薪背后是"高利润+高分配"模式 胖东来创始人于东来曾表示,企业利润的90%以上用于员工薪酬和福利,远高于行业平均水平。2024年 首季度,胖东来销售额达62亿元,全年目标200亿元,预计利润约10亿元。这些资金并未用于盲 ...
建研设计: 关于2024年度利润分配预案的公告
Zheng Quan Zhi Xing· 2025-04-03 13:11
证券代码:301167 证券简称:建研设计 公告编号:2025-010 安徽省建筑设计研究总院股份有限公司 关于 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整,没有虚假 记载、误导性陈述或重大遗漏。 特别提示: 本次利润分配预案披露后,公司不触及《深圳证券交易所创业板股票上市规 则(2024 年修订)》第 9.4 条第(八)项规定的可能被实施其他风险警示的情形。 一、审议程序 安徽省建筑设计研究总院股份有限公司(以下简称"公司")于 2025 年 4 月 于 2024 年度利润分配预案的议案》。 (一)董事会意见 董事会认为,公司 2024 年度利润分配预案兼顾公司股东的即期利益和长远 利益,同时有利于公司持续稳定发展,符合相关法律法规及《公司章程》的规定, 具有合法性、合规性、合理性。 (二)监事会意见 监事会认为,公司 2024 年度利润分配预案充分考虑了对投资者的长期、稳 定的投资回报,同时兼顾了公司盈利水平、持续发展等情况,符合有关法律、法 规、规范性文件和《公司章程》对现金分红的相关规定,不存在损害公司和股东 利益的情况。 (三)本分配预案已提交公司 2 ...
同仁堂: 同仁堂 2024年度利润分配预案公告
Zheng Quan Zhi Xing· 2025-04-03 11:15
Core Viewpoint - Beijing Tong Ren Tang Co., Ltd. plans to distribute a cash dividend of 0.50 RMB per share (including tax), based on the total share capital registered on the dividend distribution date [1] Profit Distribution Plan - The company intends to distribute a cash dividend of 5.00 RMB for every 10 shares held, amounting to a total cash dividend of approximately 44.93% based on the total share capital of 1,371,470,262 shares as of December 31, 2024 [1][2] - The total undistributed profits as of December 31, 2024, are reported at 8,386,175,950.07 RMB for the consolidated financial statements and 3,804,841,930.31 RMB for the parent company [1][2] Historical Cash Dividends - The total cash dividends for the last three fiscal years are as follows: - Current year: 1,371,470,262.00 RMB - Previous year: 685,735,131.00 RMB - Year before last: 438,870,483.84 RMB [2] - The cumulative cash dividends over the last three years amount to 2,496,075,876.84 RMB [2] Decision-Making Process - The company's board of directors approved the profit distribution plan during the seventh meeting of the tenth board on April 2, 2025, confirming it aligns with the company's profit distribution policy [3] - The supervisory board also agreed with the profit distribution plan, emphasizing its consideration of the company's profitability, operational needs, and reasonable returns for shareholders [3]
爱婴室: 关于2024年年度利润分配方案的公告
Zheng Quan Zhi Xing· 2025-04-02 13:52
证券代码:603214 证券简称:爱婴室 公告编号:2025-009 上海爱婴室商务服务股份有限公司 票上市规则》)第9.8.1条第一款第(八)项规定的可能被实施其他风险警示的情 形。 第五届董事会第八次会议、第五届监事会第七次会议审议通过了《关于制定 2024 年度利润分配预案的议案》,具体内容公告如下: 一、 利润分配方案内容 (一)利润分配方案的具体内容 根据《中华人民共和国公司法》《公司章程》的相关规定以及安永华明会计 师事务所(特殊普通合伙)出具的安永华明(2025)审字第 70012780_B01 号《审 计报告》,截至 2024 年 12 月 31 日,公司母公司报表中期末未分配利润为人民币 元。提取法定盈余公积金 6,194,496.95 元,资产负债表日累计可分配利润为 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示: ? 公司拟以实施权益分派股权登记日登记的总股本为基数,向全体股东每 ? 如在公司披露2024年度利润分配预案公告之日起至实施权益分派股权登 记日期间,因回购股份/股权激励授予 ...
现代投资: 关于2024年度利润分配预案的公告
Zheng Quan Zhi Xing· 2025-04-02 13:52
证券简称:现代投资 证券代码:000900 公告编号:2025-011 现代投资股份有限公司 关于 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚 假记载、误导性陈述或重大遗漏。 一、审议程序 现代投资股份有限公司(以下简称"公司")于 2025 年 4 月 1 日召开第九届董事会第六次会议,以 9 票赞成,0 票反对,0 票弃权 的表决结果审议通过了《2024 年度利润分配预案》,该议案尚需提 交公司 2024 年度股东大会审议。 二、2024 年度利润分配预案的基本情况 根据信永中和会计师事务所(特殊普通合伙)对公司出具的 2024 年度审计报告,公司 2024 年度母公司净利润 269,988,918.41 元。根 据《公司章程》规定,提取 10%的法定盈余公积金 26,998,891.84 元, 本年度可供分配利润 242,990,026.57 元。截至 2024 年 12 月 31 日, 公司合并报表累计未分配利润为 7,732,025,636.52 元,母公司累计 未分配利润为 7,326,998,780.50 元。根据合并报表、母公司报表中 可 ...
银禧科技: 关于公司2024年度拟不进行利润分配的专项说明
Zheng Quan Zhi Xing· 2025-04-02 13:52
为保障公司正常生产经营和未来发展,依据《公司法》及《公司章程》等相 关规定,公司2024年度拟不进行利润分配,亦不实施资本公积金转增股本。本利 润分配预案尚需提交公司2024年年度股东大会审议。 二、公司2024年度不进行利润分配的原因 根据《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规 范运作》相关规定:公司应当以合并报表、母公司报表中可供分配利润孰低的原 则来确定具体的利润分配总额和比例。根据中国证券监督管理委员会《关于进一 步落实上市公司现金分红有关事项的通知》、《上市公司监管指引第3号——上市 公司现金分红》等的相关规定,母公司及合并报表的累计未分配利润为负数。经 公司董事会讨论,公司2024年度拟不进行利润分配,亦不实施资本公积金转增股 本,公司拟定的有关利润分配方案尚需经2024年度股东大会审议。 公司董事会仍将按照相关法律法规和《公司章程》等规定,重视对投资者的 合理投资回报,从有利于公司发展和投资者回报的角度出发,综合考虑与利润分 配相关的各种因素,严格执行公司的利润分配制度,与广大投资者共享公司发展 成果。 三、董事会意见 广东银禧科技股份有限公司 关于公司 2024 年度拟 ...
博瑞医药: 2024年年度利润分配方案公告
Zheng Quan Zhi Xing· 2025-04-02 13:42
Core Viewpoint - The company plans to distribute a cash dividend of 0.096 CNY per share, amounting to a total of approximately 40.52 million CNY, which represents 21.42% of the net profit attributable to shareholders for the year [1][2][3] Profit Distribution Plan - The profit distribution is based on the total share capital registered on the equity distribution record date, with a proposed cash dividend of 0.96 CNY for every 10 shares held [1][2] - The total number of shares eligible for distribution is 422,106,055, after excluding 363,461 shares held in the company's repurchase account [1][2] - The cash dividend distribution plan is subject to approval at the company's 2024 annual general meeting [2][8] Financial Performance - For the reporting period, the company achieved a revenue of 1.28 billion CNY, reflecting an 8.74% year-on-year increase [4] - The net profit attributable to shareholders was approximately 189.17 million CNY, a decrease of 6.57% compared to the previous year [4][5] - The company’s cumulative undistributed profits as of December 31, 2024, amounted to 561.12 million CNY [1][3] R&D Investment - The company has increased its R&D investment to approximately 311.79 million CNY, a 25.42% increase year-on-year, representing 24.31% of its revenue [5][6] - The R&D investment for innovative drugs and inhalation formulations accounted for 62.78% of total R&D spending, with significant year-on-year growth [6][7] Business Strategy and Development - The company focuses on high-tech pharmaceutical manufacturing, emphasizing innovation in generic drugs, complex formulations, and original new drugs [4][5] - The company is in a critical growth phase, requiring substantial funding for R&D and operational needs, which will be supported by retained earnings and other financing channels [4][6] Shareholder Engagement - The company has implemented measures to facilitate shareholder participation in the cash dividend decision-making process, including in-person and online voting options for the annual general meeting [6][7]